Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (March 2019)
26 slides from Genetic Technologies's investor presentation, Mar 20, 2019
Slide 1: Genetic Technologies Limited March 2019
Genetic Technologies Limited March 2019
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance
Slide 3: Who we are
Who we are Research and Development leader in the genomics sector – Developing and commercialising a suite of genetic risk assessment products to prevent morbidity and mortality across a range of diseases – 20 years experience bringing genomics products to market – Progressive R&D and commercialisat
Slide 4: Corporate Overview
Genetic Technologies Limited Melbourne, Victoria, Australia Technical and corporate support with laboratory globally certified to ISO, RCPA, NATAand CLIA Phenogen Sciences Inc. Charlotte, North Carolina, U.S Sales and marketing, customer support, reimbursement management and sample accessioning to L
Slide 5: Breast Cancer Risk Assessment
Breast Cancer Risk Assessment BREVAGenplus®, is a first-to-market, clinically validated risk assessment test for non-hereditary breast cancer ▪ Simple cheek swab based test that helps determine a woman’s risk of developing sporadic breast cancer ▪ First test of its kind to be clinically validated to
Slide 6: Enhanced Breast Cancer Test
Enhanced Breast Cancer Test ▪ 15% of breast cancers are hereditary – 5-10% of breast cancers are caused by BRCA1 / BRCA2 mutations – 5-10% are unknown hereditary cancers ▪ 85% of breast cancer cases are non-hereditary (sporadic) – Less than 15% of women who get breast cancer have a family history –
Slide 7: Sporadic Breast Cancer Statistics
Sporadic Breast Cancer Statistics 7
Slide 8: Precision Medicine
Precision Medicine ▪ 1 in eight women will get breast cancer in their lifetime ▪ Screening programs that test all women at the same intervals will be overscreening 7 women and underscreening 1 woman. Our breast cancer risk assessment test offers the potential for more efficient use of screening reso
Slide 9: Early Detection = Better Outcomes
Early Detection = Better Outcomes ▪ Each year, 240,000+ new breast cancer cases are diagnosed in the US. ▪ 40,000+ will die. ▪ With early detection, >95% of these women can survive.* Breast Cancer Develops Before It Is Detected – “Know Your Risk” *http://www.cancer.org/cancer/breastcancer/detailedgu
Slide 10: GTG Market Advantage
GTG Market Advantage ▪ All of our tests are clinically validated. – Physicians are authorised to action the results without further testing. – Higher level of trust in the accuracy of our tests as compared to competitive genomic testing ▪ Our laboratory holds a range of accreditations. – CLIA - Clin
Slide 11: GTG’s Intellectual Property
GTG’s Intellectual Property ▪ 4 Patents granted in U.S. – Patent Nos. 9,051,617 and 9,068,229 covering three of the core genetic markers included in the BREVAGenplus risk assessment test – Patent No. 7,127,355 offering broad protection re: methods of genetic analysis (the concept of combining clinic
Slide 12: Scientific Authority
Scientific Authority Dr. Richard Allman, GTG Scientific Director – Strong publication record in genetic epidemiology across multiple disease categories – Collaboration for peer review and statistical validation Richard Allman, GTG Scientific Director BSc Microbiology PhD Microbiology (Flow Cytometri
Slide 13: National Health and Medical Research Council
National Health and Medical Research Council University of Melbourne NHMRC Partnership Grant – National Health and Medical Research Council is Australia's peak funding body for medical research. – Collaboration with Professor John Hopper Professor John Hopper • PhD in Mathematical Statistics • NHMRC
Slide 14: Collaboration with University of Melbourne
Collaboration with University of Melbourne ▪ Australia’s peak university ▪ Ranked #32 in the world ▪ Research-intensive ▪ Global collaborations 14
Slide 15: Research into Clinical Applications
Research into Clinical Applications GTG partners with world-leading research hospitals to develop the clinical use of polygenic risk scores in treatment decisions. Research agreement is in place with Memorial Sloan Kettering (MSK) and University of Cambridge. – The research is led by Mark E. Robson,
Slide 16: Other Key Partnerships
Other Key Partnerships Ohio State University (Columbus, Ohio) – Research collaboration exploring polygenic risk as a means to more informed decision-making for women with BRCA mutations – Led by Amanda Toland, Director of Clinical Genetics and a leader in the field of breast cancer risk assessment.
Slide 17: Rapid Deployment of New Products
Rapid Deployment of New Products • Established network of academic collaborators, both in Australia and the US, accelerates the clinical validation process – Developing colon cancer test in collaboration with the University of Melbourne • GTG diagnostic operations and workflow support multiple genet
Slide 18: GTG Product Roadmap
GTG Product Roadmap 1Q 2Q 3Q 4Q 2020 2019 2019 2019 2019 * Tests are developed and market launch is scheduled. 18
Slide 19: Our Vision
Our Vision To empower individuals to manage and reduce their risk of contracting cancer and other chronic diseases We continually strive to maintain our standing as a global leader in genomics by investing in our own research capabilities and by forming partnerships with world-class/expert organisat
Slide 20: Making a Difference in China
Making a Difference in China Improved health outcomes for individuals ▪ People who know their risk of developing disease take steps to prevent it ▪ Lifestyle changes such as weight loss, physical activity and nutrition ▪ Healthcare professionals can prescribe pharmaceutical treatments to high-risk p
Slide 21: Cancer in China
Cancer in China Cancer is the leading cause of death in China, with 4.3 million new cancer cases and 2.8 million cancer deaths estimated to occur each year. That burden is expected to increase in the coming decades because of aging of the population as well as changes in lifestyle that increase canc
Slide 22: Diabetes in China
Diabetes in China T2D has become a leading public health challenge in China. In addition to environmental factors, genetic factors contribute substantially to the development of T2D. China ranks number one, with the highest number of people with diabetes. http://diabetes.diabetesjournals.org/content
Slide 23: Screening and Early Detection
Screening and Early Detection ▪ Breast cancer death rates declined 39% from 1989 to 2015 among women. The progress is attributed to improvements in early detection and screening. ▪ Prostate cancer death rates declined 52% from 1993 to 2015 among men. Attributed to national screening programs ▪ Color
Slide 24: Collaboration with Chinese Research
Collaboration with Chinese Research ▪ Contribution to science is a core value. ▪ Collaboration with experts in genomics – Population geneticists – Disease-specific investigators – Pharmaceutical research organisations ▪ Research partnerships help us to continually refine our test protocols and bring
Slide 25: Next Steps
Next Steps ▪ Develop collaborative relationships within China – Clinical validation – Regulatory approval – Commercial channels – Laboratory testing ▪ Deliver the benefits of genetic screening into China – Go-to-market plan for additional genetic screening tests – Engagement with Key Opinion Leaders
Slide 26: Paul Kasian Chairman and CEO
Paul Kasian Chairman and CEO Email: paul.kasian@gtglabs.com Web: www.gtgcorporate.com Commercial in Confidence
Genetic Technologies — Investor Presentation (March 2019) on 6ix